LRRK2 G2019S mutations cause autosomal dominant PD through hyperactivation that impairs vesicular trafficking via Rab GTPase phosphorylation. Multiple Phase 1 programs (DNL151, BIIB094) have demonstrated target engagement (>90% Rab10 dephosphorylation) with manageable safety profiles. Lung toxicity (lamellar body accumulation) represents a dose-limiting concern requiring intermittent dosing strategies. The biomarker (Rab10 phosphorylation) enables patient selection and response monitoring.
No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRRK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.